These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Irreversible electroporation enhances delivery of gemcitabine to pancreatic adenocarcinoma. Bhutiani N; Agle S; Li Y; Li S; Martin RC J Surg Oncol; 2016 Aug; 114(2):181-6. PubMed ID: 27393627 [TBL] [Abstract][Full Text] [Related]
44. Irreversible electroporation: a novel therapy for stage III pancreatic cancer. Weiss MJ; Wolfgang CL Adv Surg; 2014; 48():253-8. PubMed ID: 25293620 [No Abstract] [Full Text] [Related]
45. Changes of apoptosis in tumor tissues with time after irreversible electroporation. Kim HB; Sung CK; Baik KY; Moon KW; Kim HS; Yi JH; Jung JH; Moon MH; Choi OK Biochem Biophys Res Commun; 2013 Jun; 435(4):651-6. PubMed ID: 23688425 [TBL] [Abstract][Full Text] [Related]
46. Irreversible electroporation in locally advanced pancreatic cancer: A call for standardization of energy delivery. Martin RC; Durham AN; Besselink MG; Iannitti D; Weiss MJ; Wolfgang CL; Huang KW J Surg Oncol; 2016 Dec; 114(7):865-871. PubMed ID: 27546233 [TBL] [Abstract][Full Text] [Related]
47. Real-time prediction of patient immune cell modulation during irreversible electroporation therapy. Beitel-White N; Martin RCG; Li Y; Brock RM; Allen IC; Davalos RV Sci Rep; 2019 Nov; 9(1):17739. PubMed ID: 31780711 [TBL] [Abstract][Full Text] [Related]
48. Safety and feasibility of Irreversible Electroporation (IRE) in patients with locally advanced pancreatic cancer: results of a prospective study. Paiella S; Butturini G; Frigerio I; Salvia R; Armatura G; Bacchion M; Fontana M; D'Onofrio M; Martone E; Bassi C Dig Surg; 2015; 32(2):90-7. PubMed ID: 25765775 [TBL] [Abstract][Full Text] [Related]
49. Controllable Moderate Heating Enhances the Therapeutic Efficacy of Irreversible Electroporation for Pancreatic Cancer. Edelblute CM; Hornef J; Burcus NI; Norman T; Beebe SJ; Schoenbach K; Heller R; Jiang C; Guo S Sci Rep; 2017 Sep; 7(1):11767. PubMed ID: 28924200 [TBL] [Abstract][Full Text] [Related]
50. Animal Models of Gastrointestinal and Liver Diseases. The difficulty of animal modeling of pancreatic cancer for preclinical evaluation of therapeutics. Logsdon CD; Arumugam T; Ramachandran V Am J Physiol Gastrointest Liver Physiol; 2015 Sep; 309(5):G283-91. PubMed ID: 26159697 [TBL] [Abstract][Full Text] [Related]
51. Patient Derived Xenografts Expand Human Primary Pancreatic Tumor Tissue Availability for Brock RM; Beitel-White N; Coutermarsh-Ott S; Grider DJ; Lorenzo MF; Ringel-Scaia VM; Manuchehrabadi N; Martin RCG; Davalos RV; Allen IC Front Oncol; 2020; 10():843. PubMed ID: 32528898 [TBL] [Abstract][Full Text] [Related]
52. Systematic review of irreversible electroporation in the treatment of advanced pancreatic cancer. Moir J; White SA; French JJ; Littler P; Manas DM Eur J Surg Oncol; 2014 Dec; 40(12):1598-604. PubMed ID: 25307210 [TBL] [Abstract][Full Text] [Related]
53. Intra-operative navigation of a 3-dimensional needle localization system for precision of irreversible electroporation needles in locally advanced pancreatic cancer. Bond L; Schulz B; VanMeter T; Martin RC Eur J Surg Oncol; 2017 Feb; 43(2):337-343. PubMed ID: 27727027 [TBL] [Abstract][Full Text] [Related]
54. Identification of novel vascular projections with cellular trafficking abilities on the microvasculature of pancreatic ductal adenocarcinoma. Hexige S; Ardito-Abraham CM; Wu Y; Wei Y; Fang Y; Han X; Li J; Zhou P; Yi Q; Maitra A; Liu JO; Tuveson DA; Lou W; Yu L J Pathol; 2015 Jun; 236(2):142-154. PubMed ID: 25561062 [TBL] [Abstract][Full Text] [Related]
55. Antitumor efficacy of liposome-encapsulated NVP-BEZ 235 in combination with irreversible electroporation. Tian L; Qiao Y; Lee P; Wang L; Chang A; Ravi S; Rogers TA; Lu L; Singhana B; Zhao J; Melancon MP Drug Deliv; 2018 Nov; 25(1):668-678. PubMed ID: 29482386 [TBL] [Abstract][Full Text] [Related]
56. Histological analysis of human pancreatic carcinoma following irreversible electroporation in a nude mouse model. Su JJ; Xu K; Wang PF; Zhang HY; Chen YL World J Gastrointest Oncol; 2018 Dec; 10(12):476-486. PubMed ID: 30595801 [TBL] [Abstract][Full Text] [Related]
58. Electroporation with Cisplatin against Metastatic Pancreatic Cancer: Michel O; Kulbacka J; Saczko J; Mączyńska J; Błasiak P; Rossowska J; Rzechonek A Biomed Res Int; 2018; 2018():7364539. PubMed ID: 29750170 [TBL] [Abstract][Full Text] [Related]
59. The feasibility of irreversible electroporation for the treatment of breast cancer and other heterogeneous systems. Neal RE; Davalos RV Ann Biomed Eng; 2009 Dec; 37(12):2615-25. PubMed ID: 19757056 [TBL] [Abstract][Full Text] [Related]
60. Early Immunologic Response of Irreversible Electroporation versus Cryoablation in a Rodent Model of Pancreatic Cancer. White SB; Zhang Z; Chen J; Gogineni VR; Larson AC J Vasc Interv Radiol; 2018 Dec; 29(12):1764-1769. PubMed ID: 30316676 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]